Array Rises As COLUMBUS Clears Phase III Melanoma Hurdle

Shares in Array Biopharma shot up by more than 80% on the release of top-line Phase III data from its COLUMBUS study of encorafenib and binimetinib, but more details are needed to gauge how the combination may fare against Novartis and Roche’s more established combos, and the newer IO therapies.

SC1609_OldWorldMap_1200x675
• Source: Shutterstock

Early data from the Phase III COLUMBUS study looking at a combination of Array BioPharma Inc.’s BRAF inhibitor encorafenib (LGX818) and MEK inhibitor binimetinib (MEK162) proved positive, sending the company's stock price soaring, though more information is needed to assess the competitive prospects for what would be the third BRAF/MEK inhibitor duo to market.

Top-line data from the first part of the Phase III study in patients with BRAF-mutant advanced, unresectable or metastatic melanoma...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category